{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:53:39Z","timestamp":1781607219760,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Primary vaginal cancer (PVC) accounts for 1\u20132% of all gynecological malignancies. Therefore, clinical trials lack and there is a paucity of approved medications beyond radiation or chemoradiation as main first line therapy. The GOG 240 and the Keynote 826 have shown significant improvements in survival in cervical cancer patients. Both concepts are approved medications for the treatment of advanced, recurrent or metastastic cervical cancer. However, the efficacy of Bevacizumab and Pembrolizumab and other Immunotherapies in PVC is mainly unknown. This study evaluates the efficacy and potential of targeted therapies and immunotherapies in patients with metastatic primary vaginal cancer, based on therapeutic strategies established for cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, 6 patients with metastatic PVC were treated with Carboplatin\/Paclitaxel\/Bevacizumab with or without Pembrolizumab. Due to Her2neu expression one patient was treated with Her2neu targeted therapy and one patient is on Nivolumab at present.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>4 patients received Bevacizumab (Bev) in addition to Carboplatin (C) and Paclitaxel (Pac). Duration of response was 6 and 13 month and one patient is still on Bev. One patient progressed after 5 cycles of C\/P\/Bev. 2 Patients were treated with Pembrolizumab (P) mono after C\/Pac\/Bev. One out of 2 patients showed a duration of response of 36 month despite late stage metastatic disease. Local progress was controlled by adjunct local radiation therapy. The other patient progressed and died. Two patients were treated with C\/Pac\/Bev\/P. One patient is still on therapy and one patient has died due to progressive disease. One patient is on Nivolumab with good response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data provide a proof of concept to adopt therapeutic modalities from cervical cancer patients in PVC patients. In addition, our findings underscore the importance of collecting real-world data to guide clinical decision-making in metastatic primary vaginal cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06267-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T02:26:35Z","timestamp":1754879195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapies in primary vaginal cancer"],"prefix":"10.1007","volume":"151","author":[{"given":"Laura Tasc\u00f3n","family":"Padr\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milka","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thore","family":"Thiesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia A.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mustea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva K.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"8","key":"6267_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ et al (2014) Improved survival with bevacizumab in advanced cervical Cancer. N Engl J Med 370(8):734\u2013743. https:\/\/doi.org\/10.1056\/NEJMoa1309748","journal-title":"N Engl J Med"},{"issue":"10103","key":"6267_CR2","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240). Lancet 390(10103):1654\u20131663. https:\/\/doi.org\/10.1016\/S0140-6736(17)31607-0","journal-title":"Lancet"},{"issue":"36","key":"6267_CR3","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS et al (2023) First-line pembrolizumab\u2009+\u2009chemotherapy versus placebo\u2009+\u2009chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. JCO 41(36):5505\u20135511. https:\/\/doi.org\/10.1200\/JCO.23.00914","journal-title":"JCO"},{"issue":"20","key":"6267_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D et al (2021) Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer. N Engl J Med 385(20):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa2112435","journal-title":"N Engl J Med"},{"issue":"6","key":"6267_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.bpobgyn.2015.01.006","volume":"29","author":"S Rajaram","year":"2015","unstructured":"Rajaram S, Maheshwari A, Srivastava A (2015) Staging for vaginal cancer. Best Pract Res Clin Obstet Gynecol 29(6):822\u2013832. https:\/\/doi.org\/10.1016\/j.bpobgyn.2015.01.006","journal-title":"Best Pract Res Clin Obstet Gynecol"},{"issue":"8","key":"6267_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/ijgc-2023-004695","volume":"33","author":"RA Nout","year":"2023","unstructured":"Nout RA, Calaminus G, Planchamp F et al (2023) ESTRO\/ESGO\/SIOPe guidelines for the management of patients with vaginal cancer. Int J Gynecol Cancer 33(8):1185\u20131202. https:\/\/doi.org\/10.1136\/ijgc-2023-004695","journal-title":"Int J Gynecol Cancer"},{"key":"6267_CR7","unstructured":"Diagnosis T (2018) and Follow\u2013Up Care of Vaginal Cancer and its Precursors. Guideline of the DGGG and OEGGG (S2k\u2013Level, AWMF Registry No. 032\/042, October"},{"issue":"3","key":"6267_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"31","key":"6267_CR9","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T et al (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkmate 358 trial. JCO 37(31):2825\u20132834. https:\/\/doi.org\/10.1200\/JCO.19.00739","journal-title":"JCO"},{"issue":"1","key":"6267_CR10","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41598-021-83317-7","volume":"11","author":"JA How","year":"2021","unstructured":"How JA, Jazaeri AA, Soliman PT et al (2021) Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 11(1):3667. https:\/\/doi.org\/10.1038\/s41598-021-83317-7","journal-title":"Sci Rep"},{"issue":"2","key":"6267_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"14","key":"6267_CR12","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.3390\/jcm12144646","volume":"12","author":"Y Sato","year":"2023","unstructured":"Sato Y, Okamoto K, Kawano Y et al (2023) Novel biomarkers of gastric cancer: current research and future perspectives. JCM 12(14):4646. https:\/\/doi.org\/10.3390\/jcm12144646","journal-title":"JCM"},{"key":"6267_CR13","doi-asserted-by":"publisher","first-page":"686879","DOI":"10.3389\/fimmu.2021.686879","volume":"12","author":"EK Egger","year":"2021","unstructured":"Egger EK, Ralser DJ, Lindner K et al (2021) Diagnostic and therapeutic approach in a metastatic vaginal adenocarcinoma: A case report. Front Immunol 12:686879. https:\/\/doi.org\/10.3389\/fimmu.2021.686879","journal-title":"Front Immunol"},{"issue":"4","key":"6267_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.2013.817","volume":"110","author":"N Wang","year":"2014","unstructured":"Wang N, Zhan T, Ke T et al (2014) Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer 110(4):1034\u20131044. https:\/\/doi.org\/10.1038\/bjc.2013.817","journal-title":"Br J Cancer"},{"issue":"2","key":"6267_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ygyno.2013.02.004","volume":"129","author":"GL Larsson","year":"2013","unstructured":"Larsson GL, Helenius G, Andersson S, Sorbe B, Karlsson MG (2013) Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. Gynecol Oncol 129(2):406\u2013411. https:\/\/doi.org\/10.1016\/j.ygyno.2013.02.004","journal-title":"Gynecol Oncol"},{"issue":"12","key":"6267_CR16","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1111\/aogs.14260","volume":"100","author":"CL Rasmussen","year":"2021","unstructured":"Rasmussen CL, Bertoli HK, Sand FL, Kj\u00e6r AK, Thomsen LT, Kj\u00e6r SK (2021) The prognostic significance of HPV, p16, and p53 protein expression in vaginal cancer: a systematic review. Acta Obstet Gynecol Scand 100(12):2144\u20132156. https:\/\/doi.org\/10.1111\/aogs.14260","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"18","key":"6267_CR17","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.3390\/cancers15184633","volume":"15","author":"FA Stuebs","year":"2023","unstructured":"Stuebs FA, Dietl AK, Koch MC et al (2023) Cytology and HPV Co-Testing for detection of vaginal intraepithelial neoplasia: a retrospective study. Cancers 15(18):4633. https:\/\/doi.org\/10.3390\/cancers15184633","journal-title":"Cancers"},{"issue":"5","key":"6267_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41379-019-0437-z","volume":"33","author":"L Voltaggio","year":"2020","unstructured":"Voltaggio L, McCluggage WG, Iding JS, Martin B, Longacre TA, Ronnett BM (2020) A novel group of HPV-related adenocarcinomas of the lower anogenital tract (vagina, vulva, and anorectum) in women and men resembling HPV-related endocervical adenocarcinomas. Mod Pathol 33(5):944\u2013952. https:\/\/doi.org\/10.1038\/s41379-019-0437-z","journal-title":"Mod Pathol"},{"key":"6267_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fonc.2019.01067","volume":"9","author":"CA Kunos","year":"2019","unstructured":"Kunos CA, Andrews SJ, Moore KN, Chon HS, Ivy SP (2019) Randomized phase II trial of triapine-cisplatin-radiotherapy for locally advanced stage uterine cervix or vaginal cancers. Front Oncol 9:1067. https:\/\/doi.org\/10.3389\/fonc.2019.01067","journal-title":"Front Oncol"},{"issue":"16suppl","key":"6267_CR20","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1200\/JCO.2023.41.16_suppl.5502","volume":"41","author":"CA Leath","year":"2023","unstructured":"Leath CA, Deng W, Mell LK et al (2023) Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase III randomized trial. JCO 41(16suppl):5502\u20135502. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5502","journal-title":"JCO"},{"issue":"6","key":"6267_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","volume":"25","author":"BT Li","year":"2024","unstructured":"Li BT, Meric-Bernstam F, Bardia A et al (2024) Trastuzumab Deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 25(6):707\u2013719. https:\/\/doi.org\/10.1016\/S1470-2045(24)00140-2","journal-title":"Lancet Oncol"},{"issue":"7","key":"6267_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7):797\u2013805. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03028.x","journal-title":"Histopathology"},{"issue":"7","key":"6267_CR23","doi-asserted-by":"publisher","first-page":"e28923","DOI":"10.1016\/j.heliyon.2024.e28923","volume":"10","author":"X Ma","year":"2024","unstructured":"Ma X, Xue L, Ou K et al (2024) Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: a case report. Heliyon 10(7):e28923. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28923","journal-title":"Heliyon"},{"key":"6267_CR24","doi-asserted-by":"publisher","unstructured":"Zhao H, Shen C, Laureano JJ et al (2024) Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat Published Online November 22. https:\/\/doi.org\/10.1007\/s10549-024-07552-y","DOI":"10.1007\/s10549-024-07552-y"},{"issue":"6","key":"6267_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732\u2013742. https:\/\/doi.org\/10.1016\/S1470-2045(17)30312-1","journal-title":"Lancet Oncol"},{"issue":"12","key":"6267_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s40265-024-02111-7","volume":"84","author":"R Kester","year":"2024","unstructured":"Kester R, Zalani S, Ebbinghaus S, Rubin E (2024) The utilization of the accelerated approval pathway in oncology: A case study of pembrolizumab. Drugs 84(12):1579\u20131601. https:\/\/doi.org\/10.1007\/s40265-024-02111-7","journal-title":"Drugs"},{"issue":"17","key":"6267_CR27","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. JCO 37(17):1470\u20131478. https:\/\/doi.org\/10.1200\/JCO.18.01265","journal-title":"JCO"},{"key":"6267_CR28","unstructured":"Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln gem\u00e4\u00df \u00a7 35a SGB V pembrolizumab (Zervixkarzinom, PD-L1 positiv). Published online November 2022. https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/fruehe-nutzenbewertung\/pembrolizumab\/pembrolizumab-zervixkarzinom-ago-dggg-dgho-noggo-20221122-korr.pdf.)"},{"key":"6267_CR29","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.gore.2021.100878","volume":"38","author":"J Ansari","year":"2021","unstructured":"Ansari J, Eltigani Mohmmed Y, Ghazal-Aswad S et al (2021) Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. Gynecol Oncol Rep 38:100878. https:\/\/doi.org\/10.1016\/j.gore.2021.100878","journal-title":"Gynecol Oncol Rep"},{"issue":"11","key":"6267_CR30","doi-asserted-by":"publisher","first-page":"e003156","DOI":"10.1136\/jitc-2021-003156","volume":"9","author":"O Klein","year":"2021","unstructured":"Klein O, Kee D, Gao B et al (2021) Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. J Immunother Cancer 9(11):e003156. https:\/\/doi.org\/10.1136\/jitc-2021-003156","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6267_CR31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1159\/000535041","volume":"17","author":"MG Vitale","year":"2024","unstructured":"Vitale MG, Nasso C, Ricc\u00f2 B et al (2024) Pembrolizumab in vaginal carcinoma: A case report and review of the literature. Case Rep Oncol 17(1):564\u2013572. https:\/\/doi.org\/10.1159\/000535041","journal-title":"Case Rep Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06267-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:08:37Z","timestamp":1781604517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06267-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["6267"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06267-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Faculty of Medicine at the University of Bonn, Germany (Nr: 328\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave informed consent for the use of their data within our biobank initiative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All patients gave informed consent for the use of their data within our biobank initiative.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"228"}}